EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment of epidemiological cutoff values against Purpureocillium lilacinum

Dallas J Smith iD, Marisa L Winkler iD, Philippe J Dufresne, Warda Memon, Julianne V Kus iD, Lisa McTaggart iD, Yalong Li, Rodrigo Almeida-Paes iD, Gloria M González, Huan Mei, Ruoyu Li, Jasmijn Jansen und 10 weitere

Journal of Clinical Microbiology · 2026

DOI: 10.1128/jcm.00793-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2026. Verfasst von Dallas J Smith und 21 weiteren Autor:innen. Beteiligte Einrichtung: Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Hypocreales, Hyalohyphomycosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, Fundação Carlos Chagas Filho de Apoio à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpureocillium lilacinum , a common environmental fungus, can cause hyalohyphomycosis with varied clinical manifestations. Mortality rates can reach 20% with invasive disease. P. lilacinum is intrinsically resistant to amphotericin B, leaving few treatment options. In the absence of clinical breakpoints, epidemiological cutoff values (ECVs) can aid clinicians in monitoring antifungal resistance trends and in guiding initial therapy. We performed antifungal susceptibility testing (AFST) on P. lilacinum isolates to establish minimum inhibitory concentration (MIC) and minimum effective concentration (MEC) distributions and ECVs. Data were collected from 13 laboratories located in seven countries. AFST was performed by broth microdilution (CLSI M38 standard) for itraconazole, voriconazole, posaconazole, isavuconazole, terbinafine, flucytosine, amphotericin B, natamycin, and manogepix. ECVs were established using the iterative statistical method with ECOFFinder (v2.1) following CLSI M57 guidelines. Results from 479 P. lilacinum isolates were analyzed. ECVs were 1 μg/mL for voriconazole, 2 μg/mL for posaconazole, 4 μg/mL for isavuconazole, and 2 μg/mL for terbinafine. Itraconazole displayed a trimodal MIC distribution, although almost all MICs were ≥0.5 µg/mL (mode, 16 μg/mL). Amphotericin B, natamycin, and flucytosine MICs were truncated at the high end of the range and consistent with intrinsic resistance. The manogepix modal MEC was 0.008 μg/mL. These proposed P. lilacinum ECVs and MIC/MEC distributions provide baseline data to monitor resistance trends. Our results confirm that P. lilacinum is intrinsically resistant (IR) to amphotericin B and likely IR to natamycin and flucytosine. Caution is needed in interpreting itraconazole results due to high interlaboratory variability. IMPORTANCE Purpureocillium lilacinum is a hyaline mold commonly found in the environment and used as an agricultural biopesticide. Infections caused by P. lilacinum can range from fungal eye infections to life-threatening pulmonary and disseminated disease, and mortality rates can be high (up to 20%). Single-center studies examining antifungal susceptibility testing (AFST) data found reduced susceptibility to certain antifungals, but more robust global AFST studies are needed to help interpret MICs and MECs. We performed AFST according to the Clinical Laboratory and Standards Institute reference method in thirteen independent laboratories on 479 P. lilacinum isolates to establish MIC/MEC distributions and epidemiological cutoff values (ECVs) for nine antifungals, including those recommended by global treatment guidelines. The calculated ECVs were 1 μg/mL for voriconazole, 2 μg/mL for posaconazole, 4 μg/mL for isavuconazole, and 2 μg/mL for terbinafine. Our results also confirm that P. lilacinum is intrinsically resistant to amphotericin B and likely intrinsically resistant to natamycin and flucytosine. Caution is needed in interpreting itraconazole AFST results due to high interlaboratory variability. These antifungal in vitro susceptibility data suggest limited options to treat P. lilacinum infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsHypocrealesHyalohyphomycosisMicrobial Sensitivity TestsHumansDrug Resistance, Fungal

Stichwörter der Autor:innen

Purpureocillium lilacinumantifungal resistanceepidemiological cutoff valueshyalohyphomycosis

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA.
  • Laboratoire de santé publique du Québec, Institut national de santé publique du Québec (INSPQ), Québec, Canada.
  • Microbiology Laboratory, Johns Hopkins Hospital, Baltimore, Maryland, USA.
  • Public Health Ontario, Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Dallas J Smith, Marisa L Winkler, Julianne V Kus, Lisa McTaggart, Rodrigo Almeida-Paes, Yinggai Song, Jos Houbraken, Ferry Hagen, Amir Seyedmousavi, Sean X Zhang, Mariana Castanheira, Shawn R Lockhart, Jochem B Buil, Andrew M Borman, Nathan P Wiederhold

Förderung

  • Intramural NIH HHS
  • NIH HHS
  • Fundação Carlos Chagas Filho de Apoio à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
  • National Institutes of Health

Zitieren

APA

Smith, D. J., Winkler, M. L., Dufresne, P. J., Memon, W., Kus, J. V., McTaggart, L., Li, Y., Almeida-Paes, R., González, G. M., Mei, H., Li, R., Jansen, J., Song, Y., Houbraken, J., Hagen, F., Seyedmousavi, A., Zhang, S. X., Castanheira, M., Lockhart, S. R., …, & Wiederhold, N. P. (2026). Establishment of epidemiological cutoff values against Purpureocillium lilacinum. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00793-26

Vancouver

Smith DJ, Winkler ML, Dufresne PJ, Memon W, Kus JV, McTaggart L, et al. Establishment of epidemiological cutoff values against Purpureocillium lilacinum. Journal of Clinical Microbiology. 2026. doi:10.1128/jcm.00793-26

BibTeX
@article{Smith2026,
  author = {Smith, Dallas J and Winkler, Marisa L and Dufresne, Philippe J and Memon, Warda and Kus, Julianne V and McTaggart, Lisa and Li, Yalong and Almeida-Paes, Rodrigo and González, Gloria M and Mei, Huan and Li, Ruoyu and Jansen, Jasmijn and Song, Yinggai and Houbraken, Jos and Hagen, Ferry and Seyedmousavi, Amir and Zhang, Sean X and Castanheira, Mariana and Lockhart, Shawn R and Buil, Jochem B and Borman, Andrew M and Wiederhold, Nathan P},
  title = {Establishment of epidemiological cutoff values against Purpureocillium lilacinum},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  doi = {10.1128/jcm.00793-26}
}
Kostenlos starten →